Amundi

A material impact from COVID-19

25/03/20 -"We are slashing our EPS going into 2020 and 2021 due to both market effects (net outflows on profitable products as, even if assets might remain in the company, when investors convert risky assets ..."

PDF page sample
Pages
50
Language
English
Published on
25/03/20
Download
You may also be interested by these reports :
07/11/25
This release did not provide much information, given the recent disposal moves. The focus was thus on direct private assets, which performed well ...
06/11/25
Eurazeo has posted good figures for 9M-25, with a pick-up in both fundraising and realisations despite a difficult market. Although it has enjoyed a ...
06/11/25
9M25 figures slightly below expectations on carried interest provisions following duagon sale – CEO stays confident regarding exit pipeline
06/11/25
Tradition maintains a solid IDB growth trajectory in 3Q25, but more adverse FX effects and a weak Non-IDB business weigh on revenue growth in CHF

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO